CompletedNCT00191542
Atomoxetine with psychoeducation compared with placebo with psychoeducation for ADHD in Swedish youth
About this title
Read the official source — NCT00191542This study evaluated the effectiveness of Atomoxetine for people with ADHD.
Medication studyAges 7–15Sweden
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Atomoxetine for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 7 years to 15 years. Other eligibility criteria applied.
- Listed locations
- Gothenburg and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Sweden
- Age range
- From 7 Years to 15 Years
- Official registry ID
- NCT00191542
- Official title
Show the full official title
A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and Adolescents
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Gothenburg · Huddinge · Linköping
6 more locations
- Lund
- Mölnlycke
- Örebro
- Umeå
- Uppsala
- Vaxjo
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Atomoxetine for people with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 7 years to 15 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...